Violich Capital Management Inc. Grows Position in AbbVie Inc. $ABBV

Violich Capital Management Inc. grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 6.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 110,376 shares of the company’s stock after acquiring an additional 6,231 shares during the quarter. AbbVie comprises approximately 3.0% of Violich Capital Management Inc.’s portfolio, making the stock its 9th biggest position. Violich Capital Management Inc.’s holdings in AbbVie were worth $25,556,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. NorthCrest Asset Manangement LLC increased its stake in AbbVie by 0.8% during the 3rd quarter. NorthCrest Asset Manangement LLC now owns 133,787 shares of the company’s stock valued at $31,150,000 after purchasing an additional 1,123 shares in the last quarter. Jericho Financial LLP raised its holdings in AbbVie by 3.1% in the 3rd quarter. Jericho Financial LLP now owns 23,828 shares of the company’s stock worth $5,517,000 after acquiring an additional 725 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in AbbVie by 2.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 569,990 shares of the company’s stock worth $132,641,000 after acquiring an additional 15,340 shares during the last quarter. Intrua Financial LLC lifted its position in AbbVie by 7.6% in the 3rd quarter. Intrua Financial LLC now owns 22,307 shares of the company’s stock valued at $5,165,000 after acquiring an additional 1,581 shares in the last quarter. Finally, Rovin Capital UT ADV purchased a new stake in AbbVie during the 3rd quarter valued at $262,000. Institutional investors own 70.23% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research nudged up multiple near‑term and FY2026–FY2027 EPS estimates for AbbVie, a signal that analysts expect stronger earnings momentum into upcoming quarters. Zacks: AbbVie stock dips — key facts
• Positive Sentiment: AbbVie is expanding its oncology pipeline — it kicked off a first‑in‑human ABBV‑711 trial in advanced squamous tumors, which supports long‑term revenue diversification beyond immunology. TipRanks: ABBV starts ABBV‑711 trial
• Positive Sentiment: AbbVie continues to advance new categories: completion of first‑in‑human work on an obesity candidate (GUB014295) and other early‑stage programs suggest multiple future growth avenues. TipRanks: obesity pipeline update
• Positive Sentiment: Skyrizi again led full‑year TV ad spending — heavy, sustained marketing should support continued uptake and revenue growth for one of AbbVie’s growth drivers. FiercePharma: Skyrizi top TV ad spender
• Neutral Sentiment: AbbVie issued a topline release for epcoritamab (DuoBody CD3xCD20) from the Phase‑3 EPCORE DLBCL‑1 trial and said it will engage global regulators to discuss next steps — company statement, not a definitive approval path. PR Newswire: AbbVie topline EPCORE DLBCL‑1
• Negative Sentiment: Several market reports characterize the EPCORE readout as a clinical disappointment on survival endpoints (despite PFS signals), which triggered selling pressure in partner Genmab and put near‑term oncology upside at risk for AbbVie. That mixed/missed survival messaging is the primary reason for today’s share weakness. Seeking Alpha: Genmab down after Epkinly trial data

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of research analyst reports. UBS Group reaffirmed a “neutral” rating on shares of AbbVie in a report on Tuesday, January 13th. BMO Capital Markets reaffirmed an “outperform” rating and set a $258.00 price target on shares of AbbVie in a report on Thursday. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and boosted their price objective for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Piper Sandler restated an “overweight” rating and issued a $289.00 target price (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Finally, Citigroup decreased their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research note on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $247.84.

AbbVie Price Performance

ABBV opened at $214.38 on Monday. The company has a 50 day simple moving average of $226.80 and a two-hundred day simple moving average of $216.65. The firm has a market cap of $378.89 billion, a P/E ratio of 162.41, a PEG ratio of 0.88 and a beta of 0.36. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the company earned $3.00 EPS. AbbVie’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is currently 496.97%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.